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Hepatology, Ghent University Hospital, BelgiumThe development of hepatocellular adenomas and – more growth, hepatomegaly, hyperuricemia, hypertriglyceridemia,
rarely – carcinoma in the liver of patients with Glycogen Storage
Disease type Ia (GSDIa) is a well-known complication of the dis-
ease. The pathophysiology of adenoma and carcinoma develop-
ment in these patients is, however, hitherto largely unknown
and is thought to be related to the metabolic control of the
patient and/or the type of mutations in the G6PC gene. We report
here on a very illustrative case of adenoma and carcinoma forma-
tion in a previously undiagnosed 42 year old male GSDIa patient
(enzymatically and genetically proven). He had two episodes of
mild hypoglycaemia in childhood, never required formal treat-
ment, showed normal growth, and only mild lactate increases
after prolonged starvation. He was a long-distance runner for
most of his adult life, without the need for more than normal car-
bohydrate intake before/during exertion. To gain a better view on
the type of adenoma formed in this patient, molecular studies
were performed. We show here that in this patient with mild
GSDIa without recurrent hypoglycaemic episodes, adenoma and
carcinoma formation still occurred and that malignant transfor-
mation of adenoma here is associated with CTNNB1 mutations
and a typical mRNA proﬁle of a b-catenin activated lesion.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Glycogen Storage Disease type Ia (GSDIa) or Von Gierke’s disease
(OMIM 232200) is an autosomal recessive disease caused by
mutations in the G6PC gene encoding for glucose-6-phosphatase,
an enzyme essential in the mobilisation of glucose from liver gly-
cogen during fasting. Patients with this disease in general present
in infancy, with ketotic hypoglycaemia, lactic acidosis, poorJournal of Hepatology 20
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1 These authors contributed equally to this work.and renal insufﬁciency. Traditionally, patients have to be kept
in an anabolic state by nocturnal nasogastric tube feeding and/
or ingestion of uncooked corn starch to prevent life-threatening
hypoglycaemia and hyperlactacidemia and to achieve normal
development and growth, for the entirety of their lives. In the
second or third decade, a large majority of GSDIa patients develop
hepatocellular adenomas, some of which evolve into hepatocellu-
lar carcinoma (HCC) [1,2]. Because GSDIa is a rare disorder, the
molecular subtype of the typical adenomas in these patients is
largely unknown. On the other hand, to be able to distinguish
adenomas associated with malignant degeneration from the ade-
nomas that will not turn malignant would be very worthwhile, in
order to allow adequate selection of patients with GSDIa and ade-
nomas for tumor resection or liver transplantation.
Outside the context of GSDIa, it is becoming clear that adeno-
mas that carry risk of malignant transformation are those carrying
CTNNB1 mutations leading to an activation of b-catenin, as
opposed to the steatotic adenomas associated with HNF1A (Hepa-
tocyte Nuclear factor 1 a) mutations and the inﬂammatory adeno-
mas associated with IL6ST mutation, activating gp130 [3–5].
Until now, mutation analysis and chromosomal studies of a
total of 13 GSDIa-associated adenomas have been reported. Three
of these adenomas were CTNNB1 mutated [3,6,7]. The only ade-
noma associated with an HCC, was CTNNB1 mutated [7].Materials and methods
Patient
The patient signed a written informed consent form, approved by the local Ethical
Committee (Leuven University Hospitals, Belgium).
Pathology
The resection specimen was received fresh and eight biopsies taken from the
lesion were snap-frozen in liquid nitrogen-cooled isopentane and stored at
80 C for molecular evaluation. Standard histopathological examination and his-
tochemical stains were performed as described previously [8]. Immunohisto-
chemistry for b-catenin and glutamine synthetase was performed according to
a recently described protocol [9].10 vol. 53 j 213–217
Fig. 1. Several hepatocytes show swollen, vacuolated nuclei. Hepatocytes with
such glycogenated nuclei are mainly located in the area surrounding the portal
tract (PT) (long arrows). The cytoplasm of hepatocytes is frequently swollen and
is pale with small clumps of eosinophilic material. This ‘‘plant-like” aspect is most
pronounced in the area indicated by the small arrow and enlarged in the inset.
Original magniﬁcation 400.
Case ReportMolecular studies
Molecular studies (CTNNB1, HNF1A, and IL6ST mutation analysis and real-time
quantitative RT-PCR for LFABP1, UGT2B7, CRP, SAA, GLUL, GPR49, ANGPT1, ANG-
PT2, NTS, and HAL) were performed as described, on all eight biopsies [3,5,7].Case description
Patient history
A 42 year old male patient presented at the outpatient clinic,
with abdominal pain and cramps for 2 weeks. Clinically, hard
hepatomegaly was noted. On subsequent CT scan, a large
(23  12  14 cm) lesion was detected in the left liver lobe,
showing an irregular margin, necrotic areas, and calciﬁcations.
On MRI with contrast, multiple focal lesions mildly hyperintenseFig. 2. The adenomatous component of the multinodular lesion consists of trabecule
are consistent with a b-catenin activated adenoma. (A) Original magniﬁcation 200 and
214 Journal of Hepatology 201on T2-weighted imaging, arterially vascularised, and without late
retention, were noted. The largest lesion was in segment 5/6
(3.5 cm), 5 (3.0 cm), 7 (1.7 cm), and multiple similar lesions were
in segments 5, 6, 7, and 8 (all smaller than 2 cm). Based on the
radiological appearance, preference for adenomas was accepted.
Carcino-embryonic antigen and a-fetoprotein were not
determined.
There were no metastases within or outside of the liver, so the
lesion was resected. The patient underwent a laparoscopic left
hepatectomy with preservation of the middle hepatic vein. This
was done in a standard fashion using the surgical aspirator (CUSA
Excel, Integra Life Science Ltd, IDA Business and Technology Park,
Ireland) with minimal blood loss provided by a unilateral vascu-
lar inﬂow exclusion before starting the resection. The pathology
report of the resection specimen is described below.
As a child, between 1 and 2 years of age, the patient experi-
enced two episodes of syncope with suspected hypoglycaemia,
during viral illness. The treatment consisted of oral intake of glu-
cose. Clinically at that time there was hepatomegaly. A diagnosis
of glycogenosis was suggested but not pursued, followed-up, or
treated accordingly. On the contrary, the patient was started on
a diet for celiac disease, which he was still following at the age
of 42. He did not have a history of recurrent hypoglycaemia, noc-
turnal feeding, or lactic acidosis. The patient went through a late
puberty and growth spurt, but later displayed excellent catch-up
growth to reach 170 cm height (weight 61 kg). He never experi-
enced any problems with fasting or exertion. On the contrary,
the patient is a long-distance runner, running marathons without
apparent need for extra carbohydrates before or during exertion.
After a 12 h fast, lactate was at 4.49 mM (0.4–2.0; in fed state
1.22 mM on one occasion, 2.01 mM on another), glucose after
12 h fast was at 64 mg/dl (55–100), triglycerides at 328 mg/dl
(6180), cholesterol at 151 mg/dl (6190), and uric acid at
5.0 mg/dl (3.5–7.2). Glycaemia measured at home in the morn-
ings, in a fasting state, or when feeling weak or hungry, was con-
sistently normal. Creatine kinase and liver tests were normal.
Both echocardiography and the glomerular ﬁltration rate was
normal as well. There was no evidence of proteinuria, nor was
there any history of kidney stones. During work-up for a gastro-
enteritis episode, seven years prior to his presentation with thes of hepatocytes that show discrete nuclear atypia. The morphological features
(B) same ﬁeld at 400 magniﬁcation.
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Fig. 3. In contrast to the adenomatous part, the areas that transformed into
well-differentiated hepatocellular carcinoma show more distinct nuclear
atypia and crowding due to an increased nucleo-cytoplasmic ratio and
thickening of the trabecules. Original magniﬁcation 400.
JOURNAL OF HEPATOLOGYcurrent lesion, ultrasound revealed a ‘somewhat enlarged, homo-
geneous liver’ (no pictures stored for review).
The patient’s family history indicates no genetic predisposi-
tion. The patient has no children, has one healthy sister (routine
biochemistry and liver ultrasound were normal), and both par-
ents are alive and well around the age of 70.
At one year follow-up after the resection, the patient has
resumed his work and sports without restraint. A malignant
lesion measuring 23 cm is well outside Milan criteria for trans-
plantation. The patient has declined the theoretical option of
transplantation. Control MRIs, taken every four months, showed
no recurrence of HCC in the liver and a stable size of the remain-
ing adenomas. A chest CT revealed no lung metastases.
Pathology report of the resection specimen
The partial hepatectomy specimen measured 19  13  9 cm and
contained a multinodular tumor with a maximal diameter ofFig. 4. Mutation analysis (A) Both the adenomatous areas (A) as the parts that consist o
synthetase staining; (B) surrounding non-lesional tissue serving as an internal control o
magniﬁcation 200.
Journal of Hepatology 20118 cm. The tumor had a lightbrown color in some areas and a yel-
low to greenish aspect in other areas. Biopsies taken from the
small rim of non-tumorous liver showed normal portal tracts
and some ﬁbrosis due to compression of the tumor. Very focally,
there was some mixed steatosis. The periportal parenchyma con-
tained numerous hepatocytes with a glycogenated nucleus
(Fig. 1). Several hepatocytes also had a swollen, pale cytoplasm
with wisps and small clumps of eosinophilic staining, giving
the impression of so-called ‘‘plant-like” hepatocytes, which is
suggestive of glycogen storage disease which is not of type 0 or
4 (Fig. 1) [11]. An intense, cytoplasmic hepatocytic signal was
not seen on the PAS-staining, most likely due to wash-out of gly-
cogen during processing of the tissue.
The lesion consisted of several nodules of well-differentiated
hepatocellular carcinoma against a background of hepatocellular
adenoma. The adenomatous areas consisted of sheets of non-
steatotic hepatocytes organised as one to two cell thick plates
separated by non-dilated sinusoids and traversed by some blood
vessels. Reticulin surrounding these plates was preserved. Portal
tracts, ductular reaction, and inﬂammation were all absent. The
nuclei of the hepatocytes showed mild atypia: they were slightly
irregular and contained chromatin clumps and a distinctive
nucleolus. Based on these morphological features (Fig. 2A and
B), the adenoma was suspected to be of the b-catenin activated
subtype [9]. This was conﬁrmed by immunohistochemistry for
glutamine synthetase which showed diffuse and strong staining
of the adenomatous areas (Fig. 4A), while the surrounding, non-
lesional liver only showed a signal in hepatocytes surrounding
centrolobular veins (Fig. 4B). Nuclear expression of b-catenin
was observed in only very few hepatocytes in the adenoma. Posi-
tive staining of the hepatocytic cell membrane for b-catenin
served as an internal control.
The malignant nodules were sharply demarcated from the
adenomatous areas and consisted of hepatocyte-like cells organ-
ised in trabecular and pseudoglandular structures. The trabecules
were separated from each other by sinusoids and they were fre-
quently more than three cells thick. The reticulin pattern was
clearly lost. The nuclei were sometimes peripherally located
within the cell and were slightly more atypical than in the ade-
nomatous areas. The nucleo-cytoplasmic ratio was clearlyf malignant tumor (T) show diffuse and strong cytoplasmic staining for glutamine
nly shows some staining in the area around the centrolobular vein (CV). Original
0 vol. 53 j 213–217 215
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Case Report
increased. Bilirubin droplets were present in some of the malig-
nant nodules. Based on these features (Fig. 3), the diagnosis of
well-differentiated hepatocellular carcinoma arising in a b-cate-
nin activated hepatocellular adenoma was established. The
malignant areas showed diffuse and strong staining for glutamine
synthetase (Fig. 4A). While all malignant hepatocytes showed
positivity of the cell membrane for b-catenin, there were very
few positive nuclei.FA
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a.Diagnostic work-up for suspected glycogenosis
Glycogen phosphorylase kinase enzymatic activity on fresh red
blood cells was normal. On snap-frozen liver biopsy, glycogen
was 4.8% of wet liver weight (3.53 ± 0.45), enzymatic activity of
phosphorylase and hexose diphosphatase were normal, glucose-
6-phosphatase activity was clearly reduced to 0.36 U/g
(7.95 ± 0.51).
Mutation analysis of the G6PC gene revealed compound heter-
ozygosity for p.Arg170X (c.508C>T) in exon 4 and p.Ala192Val
(c.575C>T) in exon 5. p.Arg170X has been described as a patho-
genic mutation [10], while p.Ala192Val has not, but affects a phy-
logenetically highly conserved amino acid in a transmembrane
domain of the protein and is thus predicted to be pathogenic.ak
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1.Molecular studies of the HCC (eight biopsies)
Four random biopsies, taken from the large malignant lesion,
showed the same mutation in CTNNB1: in-frame deletion
Del7L-131L, while four other random biopsies showed another
mutation in CTNNB1: in-frame deletion del21G-98M + ins21CC.
No IL6ST or HNF1A mutations were found in any of the samples.
We performed RT-PCR analysis testing the expression of 10 genes
(LFABP1, UGT2B7, CRP, SAA, GLUL, GPR49, ANGPT1, ANGPT2, NTS,
and HAL) (Table 1). We found an mRNA expression proﬁle typical
of a b-catenin activated adenoma in all samples, with overexpres-
sion of two genes targeted by b-catenin (GLUL and GPR49) when
compared to normal liver tissues (fold change T/N ranging from
3- to 374-fold, depending on the biopsies). Taken together, these
results clearly demonstrate the presence of somatic CTNNB1 in-
frame deletions activating b-catenin in this lesion.Ta
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.Discussion
We report on a mild clinical presentation of GSDIa, where the
diagnosis was missed early in life and the patient developed nor-
mally, without symptoms or complaints and without treatment
or follow-up. Nevertheless, in adult age, the patient presented
with multiple liver adenomas, one of which had developed into
an HCC.
In the case presented here, the presence of hepatocytes with
swollen and pale cytoplasm and with glycogenated nuclei in
the tissue surrounding the resected hepatocellular carcinoma,
together with a vague history of hypoglycaemia and hepatomeg-
aly and an increased fasting lactate, set off the search for an
underlying glycogenosis. The fact the patient has an enzymati-
cally and genetically proven GSDIa and presented with adenoma-
tosis and HCC in adult age, should prompt liver specialists and
oncologists to look for GSDIa in patients presenting with adeno-
matosis and/or HCC, even when adult.216 Journal of Hepatology 2010 vol. 53 j 213–217
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The presence of hepatocytes with swollen and pale cytoplasm
is a well-known feature of GSD [11] Although glycogenated
nuclei in the periportal area are known to represent a disturbance
of glycogen metabolism, as is seen in, e.g., NASH [12], they have
hitherto not been reported as a typical feature of GSD. Therefore,
it is possible that they are related to the atypical clinical presen-
tation of this patient. If not, the presence of glycogenated nuclei
would be an additional and easy feature to prompt pathologists
and clinicians to explore underlying glycogenoses.
The association of CTNNB1 mutations with malignant degen-
eration, is well known in sporadic liver adenoma [3]. Out of the
13 GSDIa-associated adenomas reported so far, three were
CTNNB1 mutated [3,6,7]. Only one out of 13 was associated with
an HCC and was CTNNB1 mutated. We describe another case
here, where the resected malignant lesion carried different
CTNNB1 mutations and an mRNA expression proﬁle typical of a
b-catenin activation associated lesion (Table 1).
The discrepancy between the rarity of a nuclear signal for b-
catenin and the diffuse signal for its down-stream target gene
glutamine synthetase in the lesion described here is remarkable.
This has also been observed recently by Bioulac-Sage et al. in
three CTNNB1 mutated sporadic adenomas [9]. This case report
suggests that glutamine synthetase is a more sensitive marker
than b-catenin itself, when screening for possible b-catenin
mutations is performed by immunohistochemistry. This needs
to be studied and conﬁrmed in a larger series of adenomas.
Finally, several types of CTNNB1 mutations were present in
one malignant lesion here and all eight random biopsies carried
CTNNB1 mutations. This suggests that at least two adenomas
with distinct mutation types have undergone conﬂuence, either
before or after malignant transformation, but that all lesions giv-
ing rise to the malignant lesion were CTNNB1 mutated.
In a setting of organ shortage and in view of the risks associ-
ated with liver transplantation, it would be useful to gain a better
insight into the type of adenomas in GSDIa patients that are likely
to undergo malignant transformation and therefore would
strengthen the case for liver transplantation [13]. By inference
from what is know about sporadic adenomas, one would expect
these to be the CTNNB1 mutated adenomas, i.e., glutamine syn-
thetase positive or b-catenin positive on immunohistochemistry.
This is the second case of malignant transformation of a CTNNB1-
mutated GSDIa-associated adenoma. If this association conﬁrms
itself in other patients, it would affect our treatment choices in
these patients.
In conclusion, we describe a case of mild GSDIa, presenting
with liver lesions in adult age. The HCC resected from this patient
was CTNNB1 mutated, which conﬁrms the premalignant nature
of CTNNB1 mutated adenomas, also in GSDIa. Molecular studies
for CTNNB1 mutations or routine immunohistochemistry for glu-
tamine synthetase and b-catenin, performed on punction biopsiesJournal of Hepatology 201taken from adenomas in GSDIa livers, could be useful to select
patients with large and/or growing lesions for transplantation.
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